



**Figure S2.** Residual-based diagnostics of the population PK model applied to first-line brigatinib in ALK+ NSCLC patients in ALTA-1L. **a** Distribution of conditional weighted residuals (CWRES). **b** CWRES versus population predictions. **c** CWRES versus time. **d** Q-Q plot comparing the distribution of CWRES to a normal distribution. The CWRES were normally distributed and showed no trend when related to population-predicted concentrations or time, further supporting the ability of the model to describe the ALTA-1L data.

ALK+ NSCLC anaplastic lymphoma kinase-positive non-small cell lung cancer